CRANFORD, N.J., March 18, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, announced today that Chief
Executive Officer Myron Holubiak
will deliver a virtual presentation at the Spring Investor Summit
on Wednesday, March 25, 2020 at
8:50 AM ET.
Event: Spring Investor
Summit
Presentation Date:
Wednesday, March 25, 2020
Presentation Time:
8:50 AM ET
Webcast Link:
https://www.webcaster4.com/Player/Index?webcastId=33627&g=6a614df0-9eb8-433a-ad30-283a0b3fdec3&uid=5606594&sid=
Mr. Holubiak will present an update on the Company, including a
discussion of the recent positive outcome of its interim futility
analysis for the Phase 3 Mino-Lok® pivotal trial, provide an
overview of its other pipeline products, Mino-Wrap™ and Halo-Lido,
and answer questions from investors.
"Changing the Investor Summit from a traditional in-person event
to a virtual one was a prudent decision in light of the current
COVID-19 crisis," said Mr. Holubiak. "We are grateful for the
opportunity to have this platform to connect with investors and
interested parties to share our corporate strategy for the coming
months."
The Spring Investor Summit (formerly MicroCap Conference) is an
exclusive, independent conference dedicated to connecting small cap
and microcap companies with qualified investors. The Summit will be
held via webcast this year in light of the ongoing Coronavirus
epidemic.
About Citius Pharmaceuticals, Inc.
Citius is a
specialty pharmaceutical company dedicated to the development and
commercialization of critical care products, with a focus on
anti-infectives, cancer care, and unique prescription products that
use innovative, patented, or proprietary formulations of
previously-approved active pharmaceutical ingredients. We seek to
achieve leading market positions by providing therapeutic products
that address unmet medical needs. By using previously
approved drugs with substantial safety and efficacy data, we seek
to reduce the risks associated with pharmaceutical product
development and regulatory requirements. Citius develops products
that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "should," and "may" and other words and terms of similar
meaning or use of future dates. Forward-looking statements are
based on management's current expectations and are subject to risks
and uncertainties that could negatively affect our business,
operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: risks associated with conducting
our Phase 3 trial for Mino-Lok, including completing patient
enrollment, opening study sites and achieving the required number
of catheter failure events; the estimated markets for our product
candidates and the acceptance thereof by any market; our need for
substantial additional funds; risks associated with developing
Mino-Wrap, including that preclinical results may not be predictive
of clinical results and our ability to file an IND; risks related
to our growth strategy; our ability to identify, acquire, close and
integrate product candidates and companies successfully and on a
timely basis; risks relating to the results of research and
development activities; uncertainties relating to preclinical and
clinical testing; the early stage of products under development;
our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; our ability to attract,
integrate, and retain key personnel; government regulation; patent
and intellectual property matters; competition; as well as other
risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contact:
Andrew
Scott
Vice President, Corporate
Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-deliver-virtual-presentation-at-the-spring-investor-summit-301026160.html
SOURCE Citius Pharmaceuticals, Inc.